BETTER CONTROL, **FEWER LOWS**.*

Making it easier for patients to manage their diabetes – so they can live their exceptional lives.

MiniMed® 630G system
with SmartGuard™ technology

#1 PRESCRIBED **PUMP** BRAND
VISIT MEDTRONICDIABETES.COM FOR DETAILS

ASCENSIA Diabetes Care

Medtronic

57%

of patients experience hypoglycemia** at least once per night.[1]

PATIENTS' FEARS OF GOING LOW* IMPACT HOW THEY MANAGE DIABETES.

Fear of lows* can lead patients to reduce their insulin doses below recommended levels.

74% of patients with type 1 diabetes alter their insulin due to fear of hypoglycemia[2]

47.5% of patients living with diabetes do not meet their A1C goal of ≤7%[3]

10% of hypoglycemic episodes are severe enough to require medical assistance[4]

The MiniMed system with insulin pump and continuous glucose monitoring (CGM)† can calm your patients' fears and **help them meet their A1C goals.**[5]

"Because of MiniMed's SmartGuard technology, I recommend MiniMed for all of my patients."

DR. TIMOTHY GILBERT
Founder & Medical Director
Endocrinology Center of SW Louisiana

Dr. Gilbert's statement reflects his independent professional judgment. Dr. Gilbert was not compensated for the use of his image and statement. Results may vary.

52,000 real-world MiniMed users show SmartGuard technology reduces the frequency and severity of lows* without additional time spent high – so patients spend more time in range.‡

Time per day spent at 70 mg/dL or below

MiniMed system with SmartGuard feature OFF††

MiniMed system with SmartGuard feature ON††

50 FEWER MINUTES PER DAY‡ OF SHAKING, SWEATING OR FEELING WORSE[6,7]

SMARTGUARD TECHNOLOGY TAKES ACTION TO REDUCE LOWS*.

SmartGuard technology is exclusive to the MiniMed system. It is proven to reduce time spent low*,8 – so your patients can spend more time doing what matters most to them.

A MiniMed system with SmartGuard technology is superior to a pump and sensor alone.[8,9]





93%

of patients who use SmartGuard technology say they feel more secure and confident in treating their diabetes.[‡‡]

Better outcomes. Advanced protection. Greater convenience.

The MiniMed 630G system features the latest advancements in closed loop technology, with an advanced insulin pump, built-in CGM, a highly accurate glucose meter and CareLink therapy management software. The result is a complete system that drives better outcomes, while accommodating your patients' lifestyles.

COLOR SCREEN

Simple menus and auto-brightness make the pump easy for patients to use – day and night.

WATERPROOF[¶]

So patients can participate in their favorite water activities with confidence.

CareLink® software

- Provides easy access to patient data and insights
- Reduces time spent gathering data
- Gives you more productive time with patients



EXCLUSIVE CONTOUR®NEXT LINK 2.4 METER

The only FDA-approved meter with the MiniMed 630G system designed for easy and accurate[10] CGM calibration, insulin dosing, and remote bolusing.

PREDICTIVE ALERTS
Prompt patients to take action before they go low.

SMARTGUARD TECHNOLOGY
Takes action to reduce lows without increasing A1C.[8]

BOLUS WIZARD® FEATURE
Automatically calculates precise bolus doses and prevents insulin stacking.[§]

BUILT-IN CGM WITH ENLITE® SENSOR AND GUARDIAN® LINK TRANSMITTER
Gives your patients real-time numbers and trends for making good treatment decisions.

MINIMED 630G SYSTEM
Devices shown at 200% scale to show details

MEDTRONIC IS HERE FOR YOUR PATIENTS – AND FOR YOUR PRACTICE.

Medtronic offers a comprehensive support network to help your patients succeed with their new therapy, collaborating with you in their treatment.

- StartRight℠ program to help them get started on a MiniMed system
- Personalized sessions with certified product trainers
- 24-hour helpline to answer their questions personally – any time
- Flexible payment options and financial assistance for qualifying customers
- Web resources and materials at medtronicdiabetes.com
- Active online social community to help them stay connected

***** Measured as sensor glucose values. ****** Blood glucose <70 mg/dL. **†** CGM uses a special sensor to measure sugar levels just below the skin known as interstitial fluid. These sensor glucose (SG) values are different from blood glucose (BG) measurements using a BG meter. Sensor glucose values should not be used to make treatment decisions. Patients should always do a BG fingerstick to make treatment decisions. **††** 26,053 patients kept the SmartGuard feature ON 100 percent of the time and 4,817 patients kept the SmartGuard feature OFF 100 percent of the time. 8,349 patients had time in both ON and OFF. **‡** Data from only the voluntary CareLink® Personal uploads from the MiniMed 530G with Enlite system in the U.S. available from October 15, 2013 to February 1, 2016 evaluated. Significant difference between SmartGuard On vs. SmartGuard Off (p-value < 0.05). **‡‡** User evaluations. Data on file, Medtronic MiniMed, Inc., Northridge, CA. **¶** The pump is protected against the effects of continuous immersion in up to 12 feet (3.6 meters) of water for up to 24 hours at a time at the time of manufacture. This is classified as IPX8 rating. See user guide for more details. **§** The Bolus Wizard calculator does not account for manual injections, and could prompt patients to deliver more insulin than needed. Too much insulin may cause hypoglycemia. Consult with your healthcare professional for how long you need to wait after a manual injection before you can rely on the active insulin calculation of your Bolus Wizard calculator.

References

1. Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. *J Clin Endocrinol Metab*. 2006;91(6):2087–2092. **2.** Fidler C, Elmelund CT, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. *J Med Econ*. 2011;14(5):646–655. **3.** Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure and LDL goals among people with diabetes, 1988–2010. *Diabetes Care*. 2013;36(8):2271–2279. **4.** Frier, BM. The economic costs of hypoglycaemia. *Br J Diabetes Vasc Dis*. 2011;11:10–12. **5.** Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. *N Engl J Med*. 2010;363:311–320. **6.** Hypoglycemia (Low Blood Glucose). American Diabetes Association website www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html. Accessed December 2015. **7.** Not all patients experience these symptoms at 70 mg/dL. Symptoms may vary. **8.** Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. *N Engl J Med*. 2013;369(3):224–232. **9.** ASPIRE In-Home Primary efficacy endpoint (superiority test, p<0.05). Threshold Suspend Group experienced 37.5% less low sensor glucose events as measured in Low AUC at night (10 PM–8 AM) as compared to Control Group. Low AUC defined less than or equal to 65 mg/dL for more than 20 minutes (≤ 65 mg/dL > 20 minutes). **10.** Bailey T, Wallace J, Greene C, et al. Accuracy, precision, and user performance evaluation of the CONTOUR®NEXT LINK blood glucose monitoring system. Poster presented at the 7th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); February 5–8, 2014; Vienna, Austria.

Individuals portrayed are not actual patients.

Important Safety Information: MiniMed® 630G system with SmartGuard™ technology

The MiniMed 630G system with SmartGuard™ technology requires a prescription. It is intended for continuous delivery of basal insulin and administration of insulin boluses for the management of diabetes mellitus in persons 16 years of age or older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The SmartGuard feature allows one to program the pump to temporarily suspend delivery of insulin for up to two hours when the sensor glucose value falls below a predefined threshold value. The MiniMed 630G system is not intended to be used directly for making therapy adjustments or preventing or treating hypoglycemia. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user's healthcare professional. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter (BGM). A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the "Always" send mode. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day, or who are unwilling or unable to maintain contact with their healthcare professional, or whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use U100 rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. **WARNING: The SmartGuard Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set limit. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard Suspend on low feature, it is important to read the SmartGuard Suspend on low information in the Getting Started Guide and the MiniMed 630G System User Guide and discuss proper use of the SmartGuard Suspend on low feature with your healthcare professional.**

Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. Please visit **www.medtronicdiabetes.com/importantsafetyinformation** for more details.

Safety Information: CareLink® Software

CareLink software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink reports. The reports provide information that can be used to identify trends and track daily activities such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. CareLink report data is intended for use as an adjunct in the management of diabetes and NOT intended to be relied upon by itself. Nor should it be used for the treatment of medical conditions other than diabetes. Patient blood glucose levels should be monitored at least 4–6 times a day and patients and their healthcare providers familiar with the management of diabetes should consult one another prior to engaging in treatment or changes in treatment. See CareLink User Guide at medtronicdiabetes.com/support/download-library/user-guides for details.

PP-CNL-2.4-US-0094 940M14272-11 20160811

ASCENSIA Diabetes Care

Medtronic

FIND OUT MORE
CALL 800.646.4633
VISIT professional.medtronic.com